CN101031562A - 咪唑－5－羧酸类衍生物、制备方法及其应用 - Google Patents

咪唑－5－羧酸类衍生物、制备方法及其应用 Download PDF

Info

Publication number
CN101031562A
CN101031562A CNA2006800003978A CN200680000397A CN101031562A CN 101031562 A CN101031562 A CN 101031562A CN A2006800003978 A CNA2006800003978 A CN A2006800003978A CN 200680000397 A CN200680000397 A CN 200680000397A CN 101031562 A CN101031562 A CN 101031562A
Authority
CN
China
Prior art keywords
butyl
imidazole
compound
carboxylic acid
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2006800003978A
Other languages
English (en)
Other versions
CN100506818C (zh
Inventor
郭建辉
安东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Salubris Pharmaceuticals Co Ltd
Huizhou Salubris Pharmaceuticals Co Ltd
Original Assignee
Shanghai Allist Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Allist Pharmaceuticals Inc filed Critical Shanghai Allist Pharmaceuticals Inc
Publication of CN101031562A publication Critical patent/CN101031562A/zh
Application granted granted Critical
Publication of CN100506818C publication Critical patent/CN100506818C/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

本发明公开了一种咪唑－5－羧酸类衍生物以及它们的制备方法。本发明所述衍生物是血管紧张素II受体的拮抗剂，具有强有力的血管紧张素II拮抗活性和抗高血压活性，从而可用作治疗高血压的治疗剂。

Description

PCT国内申请，说明书已公开。

Claims (9)

  1. PCT国内申请，权利要求书已公开。
CNB2006800003978A 2006-02-20 2006-07-31 咪唑-5-羧酸类衍生物、制备方法及其应用 Active CN100506818C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNA2006100239910A CN101024643A (zh) 2006-02-20 2006-02-20 咪唑－5－羧酸类衍生物、制备方法及其应用
CN200610023991.0 2006-02-20
PCT/CN2006/001914 WO2007095789A1 (fr) 2006-02-20 2006-07-31 Dérivés d'acide imidazol-5-carboxylique, leurs procédés de préparation et leur utilisation

Publications (2)

Publication Number Publication Date
CN101031562A true CN101031562A (zh) 2007-09-05
CN100506818C CN100506818C (zh) 2009-07-01

Family

ID=38436915

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2006100239910A Pending CN101024643A (zh) 2006-02-20 2006-02-20 咪唑－5－羧酸类衍生物、制备方法及其应用
CNB2006800003978A Active CN100506818C (zh) 2006-02-20 2006-07-31 咪唑-5-羧酸类衍生物、制备方法及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNA2006100239910A Pending CN101024643A (zh) 2006-02-20 2006-02-20 咪唑－5－羧酸类衍生物、制备方法及其应用

Country Status (12)

Country Link
US (2) US7858651B2 (zh)
EP (1) EP1988090B1 (zh)
JP (1) JP5250760B2 (zh)
KR (1) KR101179110B1 (zh)
CN (2) CN101024643A (zh)
AU (1) AU2006338796B2 (zh)
CA (1) CA2643005C (zh)
DK (1) DK1988090T3 (zh)
ES (1) ES2424154T3 (zh)
PL (1) PL1988090T3 (zh)
PT (1) PT1988090E (zh)
WO (1) WO2007095789A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101024643A (zh) 2006-02-20 2007-08-29 上海艾力斯医药科技有限公司 咪唑－5－羧酸类衍生物、制备方法及其应用
KR101112515B1 (ko) * 2006-12-06 2012-02-24 상하이 알리스트 파마슈티컬즈 인코포레이티드 이미다졸-5- 카복실산 유도체의 염 및 그 제조방법 및 상기 염으로 구성되는 약학 조성물
CN101214242A (zh) * 2007-01-05 2008-07-09 上海艾力斯医药科技有限公司 新的药用组合物
CN101317842A (zh) * 2007-06-07 2008-12-10 上海艾力斯医药科技有限公司 一种咪唑-5-羧酸衍生物的治疗用途
CN101407511B (zh) * 2007-10-11 2013-01-09 上海艾力斯生物医药有限公司 一种结晶型的咪唑-5-羧酸衍生物
AU2009246670A1 (en) * 2008-05-15 2009-11-19 Merck Sharp & Dohme Corp. Angiotensin II receptor antagonists
CN101596189A (zh) * 2008-06-05 2009-12-09 上海艾力斯生物医药有限公司 含有咪唑-5-羧酸类衍生物的药用组合物
JP5575783B2 (ja) * 2008-12-12 2014-08-20 ファーマコステック カンパニー リミテッド トリフェニルメタン保護基の除去方法
KR101213467B1 (ko) * 2010-04-30 2012-12-20 진양제약주식회사 로자탄 대사체 이엑스피-3174 이수화물의 신규한 제조 방법
CN103012377A (zh) * 2011-09-27 2013-04-03 江苏艾力斯生物医药有限公司 一种咪唑-5-羧酸酯的重结晶方法
CN102558064B (zh) * 2012-01-29 2014-04-16 安润医药科技（苏州）有限公司 抗高血压化合物及其制备方法和应用，以及其在药学上可接受的盐
CN104610232B (zh) * 2013-11-01 2019-09-20 深圳信立泰药业股份有限公司 阿利沙坦酯无定形及其制备方法及含所述无定形的药物组合物
CN103965171A (zh) * 2014-04-30 2014-08-06 上海艾力斯医药科技有限公司 一种阿利沙坦酯的制备方法
CN106188012B (zh) * 2014-06-20 2018-11-30 深圳信立泰药业股份有限公司 一种阿利沙坦酯结晶及其制备方法及含有该结晶的药物组合物
CN105218527B (zh) * 2015-10-10 2018-04-24 江苏宝众宝达药业有限公司 一种exp-3174的制备方法
CA3016258A1 (en) 2016-01-20 2017-07-27 Jie Yan Compounds of angiotensin ii receptor antagonist metabolite and nep inhibitor, and preparation methods thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
AT398202B (de) 1991-10-04 1994-10-25 Chem Pharm Forsch Gmbh Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
ES2155827T3 (es) * 1992-06-02 2001-06-01 Sankyo Co 4-carboxiimidazoles como antagonistas de la angiotensina ii y su uso terapeutico.
JPH083162A (ja) * 1994-04-19 1996-01-09 Tanabe Seiyaku Co Ltd イミダゾピリジン誘導体及びその製法
RO118046B1 (ro) * 1995-06-07 2003-01-30 Gd Searle & Co Chicago Asociere farmaceutica
MXPA06001263A (es) * 2003-07-31 2006-04-11 Nicox Sa Derivados de nitrooxi de losartan, valsartan, candesartan, telmisartan, eprosartan y olmesartan como bloqueadores de receptor de angiotensina ii para el tratamiento de enfermedades cardiovasculares.
EP1668008A4 (en) 2003-08-28 2009-02-25 Nitromed Inc NITROSED AND NITROSYLATED DIETETIC COMPOUNDS, COMPOSITIONS AND APPLICATION METHODS
EP1884240B1 (en) 2005-04-22 2009-11-11 Daiichi Sankyo Company, Limited Pharmaceutical for prevention or treatment of bone metabolic disease
CN101024643A (zh) 2006-02-20 2007-08-29 上海艾力斯医药科技有限公司 咪唑－5－羧酸类衍生物、制备方法及其应用
KR101112515B1 (ko) 2006-12-06 2012-02-24 상하이 알리스트 파마슈티컬즈 인코포레이티드 이미다졸-5- 카복실산 유도체의 염 및 그 제조방법 및 상기 염으로 구성되는 약학 조성물
CN101214242A (zh) 2007-01-05 2008-07-09 上海艾力斯医药科技有限公司 新的药用组合物
CN101317842A (zh) 2007-06-07 2008-12-10 上海艾力斯医药科技有限公司 一种咪唑-5-羧酸衍生物的治疗用途
CN101407511B (zh) 2007-10-11 2013-01-09 上海艾力斯生物医药有限公司 一种结晶型的咪唑-5-羧酸衍生物

Also Published As

Publication number Publication date
AU2006338796B2 (en) 2011-05-12
PT1988090E (pt) 2013-08-05
USRE44873E1 (en) 2014-04-29
DK1988090T3 (da) 2013-08-05
CA2643005C (en) 2012-05-15
KR101179110B1 (ko) 2012-09-07
EP1988090A1 (en) 2008-11-05
JP5250760B2 (ja) 2013-07-31
US7858651B2 (en) 2010-12-28
CN101024643A (zh) 2007-08-29
PL1988090T3 (pl) 2013-10-31
ES2424154T3 (es) 2013-09-27
JP2009527509A (ja) 2009-07-30
CA2643005A1 (en) 2007-08-30
EP1988090A4 (en) 2010-06-30
KR20080096707A (ko) 2008-10-31
US20090036505A1 (en) 2009-02-05
WO2007095789A1 (fr) 2007-08-30
EP1988090B1 (en) 2013-05-01
CN100506818C (zh) 2009-07-01
AU2006338796A1 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
CN101031562A (zh) 咪唑－5－羧酸类衍生物、制备方法及其应用
JP2009527509A5 (zh)
RU2763287C1 (ru) Способ получения производных 4-метоксипиррола
US5137902A (en) 4-alkylimidazole derivatives and anti-hypertensive use thereof
JP5290190B2 (ja) イミダゾール−５−カルボン酸誘導体の塩、製造方法及びその医薬組成物
CN101798300B (zh) N-苯基吲哚甲基取代的双苯并咪唑衍生物及其降压等应用
CN101367795B (zh) 一种咪唑-5-羧酸衍生物及其制备方法
CN105622595A (zh) 一种阿奇沙坦酯钾盐及其中间体新的制备方法
CA2542499A1 (en) Preparation of candesartan cilexetil
CN104774197A (zh) 一种苯并咪唑衍生物的制备方法
JP3032844B2 (ja) ピリミジンジオン誘導体
WO2000031071A1 (en) 2-alkyl-5-halo-3-[2'-(tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-imidazole-4-carboxaldehyde acetal derivatives, their preparation and use
JP2007527925A (ja) 粗カンデサルタンシレキセチルの調製
JP2009102438A (ja) カンデサルタンシレキセチルの調製
JPH09323991A (ja) 新規カルボキシメチリデンシクロヘプトイミダゾール誘導体及びその製造方法並びにこれを含有する薬剤
WO1983002945A1 (en) Thiazolopyrimidine derivative

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: SHANGHAI ALLIS BIO-PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: SHANGHAI ALLIS MEDICAL TECHNOLOGY CO., LTD.

Effective date: 20090925

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20090925

Address after: Zhou Zhu Road, Shanghai, Pudong New Area No. 337

Patentee after: Shanghai Allist Pharmaceuticals, Inc.

Address before: Shanghai Zhangjiang High Tech Park Chinese Cailun Road No. 780 4 floor

Patentee before: SHANGHAI ALLIST PHARMACEUTICALS, Inc.

EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20070905

Assignee: SHANGHAI ALLIST PHARMACEUTICAL., Inc.

Assignor: Shanghai Allist Pharmaceuticals, Inc.

Contract record no.: 2010310000040

Denomination of invention: Imidazo-5-carboxylic-acid derivatives, its preparing method and use

Granted publication date: 20090701

License type: Exclusive License

Record date: 20100423

EC01 Cancellation of recordation of patent licensing contract

Assignee: SHANGHAI ALLIST PHARMACEUTICAL., Inc.

Assignor: Shanghai Allist Pharmaceuticals, Inc.

Contract record no.: 2010310000040

Date of cancellation: 20121101

LICC Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model
ASS Succession or assignment of patent right

Owner name: SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.

Free format text: FORMER OWNER: SHANGHAI ALLIST BIOMEDICAL CO., LTD.

Effective date: 20130104

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 201318 PUDONG NEW AREA, SHANGHAI TO: 201203 PUDONG NEW AREA, SHANGHAI

TR01 Transfer of patent right

Effective date of registration: 20130104

Address after: 201203 Shanghai City Harley Road, Zhangjiang hi tech Park No. 1118 5 floor

Patentee after: SHANGHAI ALLIST PHARMACEUTICALS, Inc.

Address before: 201318 Shanghai city Pudong New Area Zhu Zhou Road No. 337

Patentee before: Shanghai Allist Pharmaceuticals, Inc.

ASS Succession or assignment of patent right

Owner name: SHENZHEN SALUBRIS ASSETS MANAGEMENT CO., LTD.

Free format text: FORMER OWNER: SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.

Effective date: 20130124

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 201203 PUDONG NEW AREA, SHANGHAI TO: 518040 SHENZHEN, GUANGDONG PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20130124

Address after: 518040, Anhui building, south of Shennan Road, Shenzhen, Guangdong, 1921, Futian District

Patentee after: Shenzhen Xinlitai Asset Management Co.,Ltd.

Address before: 201203 Shanghai City Harley Road, Zhangjiang hi tech Park No. 1118 5 floor

Patentee before: SHANGHAI ALLIST PHARMACEUTICALS, Inc.

EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20070905

Assignee: SHANGHAI ALLIST PHARMACEUTICAL., Inc.

Assignor: Shenzhen Xinlitai Asset Management Co.,Ltd.

Contract record no.: 2013440020022

Denomination of invention: Imidazo-5-carboxylic-acid derivatives, its preparing method and use

Granted publication date: 20090701

License type: Common License

Record date: 20130123

Application publication date: 20070905

Assignee: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd.

Assignor: Shenzhen Xinlitai Asset Management Co.,Ltd.

Contract record no.: 2013440020020

Denomination of invention: Imidazo-5-carboxylic-acid derivatives, its preparing method and use

Granted publication date: 20090701

License type: Common License

Record date: 20130123

LICC Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model
EC01 Cancellation of recordation of patent licensing contract

Assignee: SHANGHAI ALLIST PHARMACEUTICAL., Inc.

Assignor: Shenzhen Xinlitai Asset Management Co.,Ltd.

Contract record no.: 2013440020022

Date of cancellation: 20150127

LICC Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model
ASS Succession or assignment of patent right

Owner name: SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.

Free format text: FORMER OWNER: SHENZHEN SALUBRIS ASSETS MANAGEMENT CO., LTD.

Effective date: 20150717

Owner name: HUIZHOU XINLITAI PHARMACEUTICAL CO., LTD.

Effective date: 20150717

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20150717

Address after: Shenzhen City, Guangdong Province, 518040 Shennan Road No. 6009 Che Kung Temple Green Plaza building 37 layer

Patentee after: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd.

Patentee after: HUIZHOU XINLITAI PHARMACEUTICAL Co.,Ltd.

Address before: 518040, Anhui building, south of Shennan Road, Shenzhen, Guangdong, 1921, Futian District

Patentee before: Shenzhen Xinlitai Asset Management Co.,Ltd.

CP02 Change in the address of a patent holder
CP02 Change in the address of a patent holder

Address after: Area A, 4th Floor, Digital Peninsula, No. 2, Hongliu Road, Fubao Community, Fubao Street, Futian District, Shenzhen, Guangdong, 518017

Patentee after: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd.

Patentee after: HUIZHOU XINLITAI PHARMACEUTICAL Co.,Ltd.

Address before: 518040 37 / F, main building, chegongmiao Lvjing Plaza, 6009 Shennan Avenue, Shenzhen, Guangdong

Patentee before: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd.

Patentee before: HUIZHOU XINLITAI PHARMACEUTICAL Co.,Ltd.